

Godavari Biorefineries Ltd

Dated: January 9, 2025

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

The Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Tower,
Dalal Street
Mumbai-400001

Script Symbol: GODAVARIB Script Code: 544279

Sub: Intimation of Credit Rating under SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (LODR) Regulation, 2015, we would like to inform you that CARE Rating Limited vide its press release dated 9th January, 2025 has upgraded the credit rating of **CARE BBB+ Stable** for Long Term Bank Facilities, **CARE A2** for Short Term Bank Facilities and **CARE BBB+ Stable** for Public Deposit of the Company

Press release dated 9th January, 2025 issued by CARE Rating Limited to this effect are enclosed.

This is for your information and records.

Thanking you, Yours faithfully

For Godavari Biorefineries Limited

Manoj Jain Company Secretary & Compliance Officer Membership No.F-7998





Godavari Biorefineries Limited

January 09, 2025

| Facilities/Instruments | Amount (₹ crore) | Rating ¹ | Rating Action |
|----------------------------|---------------------------------|---------------------|--------------------------------|
| Long-term bank facilities | 653.83 (Reduced from 790.94) | CARE BBB+; Stable | Upgraded from CARE BBB; Stable |
| Short-term bank facilities | 97.00 | CARE A2 | Upgraded from CARE A3+ |
| Fixed deposit | 85.00 | CARE BBB+; Stable | Upgraded from CARE BBB; Stable |

Details of instruments/facilities in Annexure-1.

Rationale and key rating drivers

The upgrade in ratings assigned to bank facilities of Godavari Biorefineries Limited (GBL) factors in recent fund-raising event via initial public offer (IPO), which not only improved the company's capital structure and debt service coverage indicators, but also its liquidity position. Moreover, the recent resumption of diversion of cane to ethanol enabling the company to benefit from existing and enhanced capacity is further expected to drive the growth of the company in the medium term. Ratings continue to benefit from GBL's strong and resourceful promoter group, its long track of operation in sugar industry, integrated sugar unit, and locational advantage. Moreover, its diversified product segment such as sugar, distillery, co-gen and biochemicals continues to lower the concentration risk. The company continues to maintain diverse customer portfolio which includes traders, oil marketing companies, personal care, flavour and fragrance, among others, and the customer concentration risk continues to remain low.

However, the above strengths remain partially offset by the working capital-intensive operations and the vulnerability of operations to agroclimatic conditions. Additionally, the profitability remains susceptible to volatile raw material prices due to it being part of a seasonal, regulated, and cyclical sugar industry.

Rating sensitivities: Factors likely to lead to rating actions

Positive factors

- Improvement in profit before interest, lease rentals, depreciation, and taxation (PBILDT) to 10% on sustained basis.
- Improvement in total debt to earnings before interest, taxation, depreciation, and amortisation (EBITDA) to below 2.5x.

Negative factors

- Deterioration in total debt to EBITDA above 3.5x.
- Sizeable deterioration in terms of profitability and cash accruals compared to the envisaged levels, leading to deterioration in the debt coverage indicators and liquidity.
- Significant elongation in the operating cycle, resulting in deterioration in liquidity position.

Analytical approach: Consolidated

CARE Ratings Limited (CARE Ratings) has taken a consolidated view of GBL, since subsidiaries are in a similar line of business and there are operational and financial linkages. The list of subsidiaries consolidated is mentioned as Annexure-6.

Outlook: Stable

The stable outlook reflects the CARE Ratings' expectations of improvement in GBL's performance owing to favourable outlook in the industry related to its key products such as ethanol and biochemicals. Also, GBL's ongoing capex plan is further expected to benefit the company in medium term.

 $^{^1}$ Complete definition of ratings assigned are available at <u>www.careedge.in</u> and other CARE Ratings Limited's publications.



Detailed description of key rating drivers:

Key strengths

Strong promoter group and a long-standing track record in the sugar industry

GBL belongs to the Somaiya group. The Somaiya group is among the oldest and well-established industrial houses in India and has diversified interests in sugar and its allied products, alcohol and bulk organic chemicals, bio-based specialty chemicals, renewable energy, printing and publishing, education, hospital, and social welfare. The Mumbai-based group runs a hospital, non-governmental organisations (NGOs), and various educational institutes across various parts of Mumbai. The promoters have time and again extended financial support to the company in the past. GBL was established by the late KJ Somaiya in 1939 as 'The Godavari Sugar Mills Limited' and is currently managed by his grandson, Samir Somaiya (Chairman and Managing Director). The company has over eight decades of track record in the sugar industry.

Locational advantage

The company has a sugarcane crushing facility at Sameerwadi, Karnataka, and a distillery and co-generation power plant. It also has another manufacturing plant engaged in the production of chemical products at Sakarwadi, Maharashtra. The sugarcane procured from Maharashtra and Karnataka have higher recovery than those procured from other regions of India, thus providing companies with manufacturing facilities in these regions better operational benefits. The gross recovery rate stood at 10.78% in FY24 (FY23: 11.76%). Thus, the location of the sugar plant is considered to be favourable considering the region being a sugarcane-producing one and it facilitates the consistent and abundant availability of sugarcane for sugar and allied manufacturing activities.

Fully integrated sugar producing unit with diversified product portfolio

GBL continues to benefit from its diversified product portfolio from the related value chain such as sugar, co-generation, distillery and biochemicals. The revenue profile is well diversified, characterised by its presence in the production of sugar, ethanol, power, and chemicals. The segment such as sugar, distillery and biochemicals, all contribute material chunk towards the revenue in H1FY25 at 45% (FY24: 33%; FY23: 34%), 20% (FY24: 33%; FY23: 31%) and 32% (FY24: 30%; FY23: 32%), respectively, and rest is contributed by power. Presently, GBL produces ethanol from canes and molasses. However, the company is incurring capex to produce ethanol from grain as well. Sugar industry being seasonal, the company continues to benefit from other products.

Expected improvement in TOI in medium term; FY24 performance was moderate:

The roll back of the restriction on diversion of cane to ethanol production, the Government's initiative to increase the use of ethanol in fuel in accordance with Ethanol Blending Programme, and favourable prices across various grades of ethanol, are expected to benefit the company in the medium-to-long term. GBL's capex plan in accordance with this programme to enhance its distillery capacity by venturing into grain-based ethanol, is further expected to aid the company in coming years. Moreover, the increasing demand for biochemicals in industries is expected to support the company going forward, considering that the company generates ~33% of its revenue from biochemicals which finds its application across industries such as paints & coatings, cosmetics, flavour, and fragrances, among others.

In FY24, GBL's TOI declined by \sim 16% with total income from operations at ₹1,686.66 crore (FY23: ₹2,014.69 crore). This decline was due to underperformance across major product segment such as sugar, distillery, and biochemicals. The curb on exports of sugar, restriction on production of ethanol and cane diversion to ethanol, price volatility in biochemicals and low global demand for the same had impacted the overall performance of the company in FY24. However, in H1FY25, the company has booked revenue of ₹843.48 crore (H1FY24: ₹673.45 crore).

Moderate profitability, expected to improve in medium term

With expected improvement in ethanol production and supply given the restoration of cane to ethanol diversion, its favourable pricing, the company's operating margin is expected to improve gradually. The exit from long-term contracts for procuring the raw material in FY24 is expected to aid the margin growth from FY25 onwards. Though the profitability remains modest in H1FY25, the second half of the financial year is the season wherein the company books significantly high EBITDA margin. The overall annual operating margin remained almost stable at 7.93% in FY24 (FY23: 7.29%).

Expected improvement in debt indicators

The company have been in capex mode since FY21 by enhancing the sugar and ethanol capacities, installation of turbines, setting of pellet plant, among others, which had resulted in leveraged capital structure. However, the recent fund-raising event of ₹325.00 crore via IPO has resulted into ₹240.00 crore of debt prepayment, thus improving its highly leveraged position.



Despite the on-going capex plans, the debt metrics is expected to improve with overall gearing expected to improve in near-to-medium term considering expected improvement in accruals and reduced debt level. Overall gearing stood at 2.79x as on March 31, 2024 (As on March 31, 2023: 3.04x). Also, the repayment for new loan availed for funding the capex is expected from FY28 onwards, further lowering immediate financial burden. The interest coverage remained moderate at 1.77x in FY24 (FY23: 2.02x). CARE Ratings observes, considering the debt prepayment, benefit of interest subvention, reduced interest rate by one of the lenders and expected improvement in EBITDA, interest coverage is expected to improve in near to medium term.

Kev weaknesses

Working capital-intensive operations

GBL's business is a working capital-intensive business because of the seasonality of the agriculture business. The company needs to procure inventory from farmers in the harvesting period. Being a well-established and among the major sugar producers in the region, GBL is able to get sugarcane from the farmers in abundance and a good credit period, post which, the company makes payments in a phased and regular manner to the farmers. Besides, GBL exports products on an advance basis and the collection period for the domestic sale of sugar to institutional customers and the sale of ethanol to oil marketing companies (OMCs) is steady at ~30 days. The company needs to maintain inventory to offer the steady supply of sugar per the requirements of institutional customers and the retail market throughout the year, and with the sugar prices gradually increasing over the sugar production cycle, it warrants a high level of inventory during the year-end. The maximum average utilisation of the company's working capital limits against the drawing power stood ~ 94% in the last 12 months ending November 30, 2024.

Project implementation and stabilisation risk

The company had a planned capex of ~ 324.00 crore over FY25-FY27 for setting up grain-based distillery, expansion of existing capacity of distillery, debottlenecking, and normal capex. The said capex will be funded by bank borrowings and internal accruals. The debottlenecking in speciality chemicals is scheduled to be completed by FY25 and grain-based distillery project is scheduled to be completed by FY26. The timeline of completion and stabilisation of the same remains crucial and their contribution towards the company's performance is a key monitorable.

Seasonal, cyclical, and regulated nature of the sugar business

The sugar industry, being directly dependent on the sugarcane crop and its yield, is susceptible to agro-climatic risks. Climatic conditions, more specifically, the monsoons, influence operational parameters for a sugar entity, such as the crushing period and sugar recovery levels. Also, the degree of dispersion of monsoon precipitation across the sugar-growing areas also leads to fluctuating trends in sugar production in different regions. CARE Ratings notes that while the gross recovery rates for GBL have been at $\sim 11\%$ for the period ended March 31, 2024, the higher recovery rates lead to a reduction in the cost of production of sugar, thus supporting the margins. The industry is cyclical by nature and is vulnerable to government policies for various reasons, like its importance in the wholesale price index (WPI) as it classifies as an essential commodity. The government on its part resorts to regulations such as fixing the raw material prices in the form of state advised prices (SAP) and fair and remunerative prices (FRP). All these factors impact the cultivation patterns of sugarcane in the country, and thus, affect the profitability of sugar companies. Hence, the company's performance can be impacted by a disproportionate increase in cane prices in particular year. The profitability remains vulnerable to the government's policies on sugar and ethanol, minimum support price (MSP), and remunerative ethanol prices.

Liquidity: Adequate

The liquidity of the company is adequate with recent fund-raising event leading to cash inflow of ₹325.00 crore. Given that these proceeds have been majorly utilised to lower its debt level, the debt service coverage ratio (DSCR) of the company is adequate. Around ₹240.00 crore of debt prepayment have resulted into lower debt burden and finance cost in the coming years. The repayment of the company now stands at ₹55.00 crore in FY25 and ₹36.00 crore in subsequent years. Out of ₹55.00 crore of repayment in FY25, ~₹49.00 crore has been repaid. The gross cash accrual (GCA) is expected to remain healthy considering expected improvement in both revenue and profitability. The company's GCA stood at ₹72.00 crore in FY24 (FY23: ₹80.80 crore). Also, the company has track record of healthy cash flow from operations, which was ₹186.67 crore in FY24. The company has sufficient sanctioned facilities for working capital, however the drawing Power is less. The utilisation of cash credit is within the drawing power. The utilisation of fund-based limits stood at ~94% and that of non-fund-based limits at ~67% for last 12 months ended November 30, 2024. The free cash and bank balance stood modest at ₹12.18 crore.



Applicable criteria

Consolidation

Definition of Default

Liquidity Analysis of Non-financial sector entities

Rating Outlook and Rating Watch

Manufacturing Companies

Sugar

<u>Financial Ratios – Non financial Sector</u>

Short Term Instruments

About the company and industry

Industry classification

| Macroeconomic indicator | Sector | Industry | Basic industry |
|----------------------------|----------------------------|------------------------------------|----------------|
| Fast moving consumer goods | Fast moving consumer goods | Agricultural food & other products | Sugar |
| | | | |

GBL was incorporated in 1939 by the late KJ Somaiya and his son, the late Dr. Shantilal K Somaiya. As on October 29, 2024, the promoter and promoter group hold 63.31% equity stake in the company through entities. GBL has two units, one is an integrated plant producing sugar, power and industrial alcohol, and second unit produces bio-based specialty chemicals. The integrated sugar plant is in Sameerwadi, Karnataka, and bio-based speciality chemical unit is in Sakarwadi, Maharashtra. Its chemicals division exports ethyl acetate to the Middle East, Africa, and European countries. The company has an in-house retail brand 'Jivana' for the sale of sugar, turmeric, and salt in Rajasthan Maharashtra, Karnataka, and Gujarat.

| Brief Financials (₹ crore) (Consolidated) | March 31, 2023 (A) | March 31, 2024 (A) | H1FY25 (UA) |
|--|--------------------|--------------------|-------------|
| Total operating income | 2014.69 | 1686.67 | 843.48 |
| PBILDT | 146.96 | 133.77 | -41.02 |
| PAT | 19.27 | 12.30 | -101.10 |
| Overall gearing (times) | 3.04 | 2.79 | NA |
| Interest coverage (times) | 2.02 | 1.77 | -1.03 |

A: Audited UA: Unaudited; NA: Not available; Note: these are latest available financial results

Status of non-cooperation with previous CRA: Not applicable

Any other information: Not applicable

Rating history for last three years: Annexure-2

Detailed explanation of covenants of rated instrument / facility: Annexure-3

Complexity level of instruments rated: Annexure-4

Lender details: Annexure-5



Annexure-1: Details of instruments/facilities

| Name of the Instrument | ISIN | Date of Issuance (DD-MM- YYYY) | Coupon Rate (%) | Maturity Date (DD- MM-YYYY) | Size of the Issue (₹ crore) | Rating Assigned and Rating Outlook |
|-----------------------------------|------|---|--------------------|-----------------------------------|-----------------------------------|---|
| Fixed Deposit | | - | - | - | 85.00 | CARE BBB+; Stable |
| Fund-based - LT-Cash Credit | | - | - | - | 276.00 | CARE BBB+; Stable |
| Fund-based - LT-Term Loan | | - | - | January 2034 | 377.83 | CARE BBB+; Stable |
| Non-fund- based - ST- BG/LC | | - | - | - | 97.00 | CARE A2 |

Annexure-2: Rating history for last three years

| | | Current Ratings | | | Rating History | | | |
|---------|--|-----------------|------------------------------------|-------------------------|---|--|---|---|
| Sr. No. | Name of the Instrument/Bank Facilities | Туре | Amount Outstanding (₹ crore) | Rating | Date(s) and Rating(s) assigned in 2024- 2025 | Date(s) and Rating(s) assigned in 2023- 2024 | Date(s) and Rating(s) assigned in 2022- 2023 | Date(s) and Rating(s) assigned in 2021- 2022 |
| 1 | Non-fund-based - ST-BG/LC | ST | 97.00 | CARE A2 | - | 1)CARE A3+ (20-Oct- 23) 2)CARE A3+ (09-Oct- 23) | 1)CARE A3+ (09-Nov- 22) | 1)CARE A3+ (19-Aug- 21) 2)CARE A3 (07-Apr- 21) |
| 2 | Fund-based - LT- Term Loan | LT | 377.83 | CARE BBB+; Stable | - | 1)CARE BBB; Stable (20-Oct- 23) 2)CARE BBB; Stable (09-Oct- 23) | 1)CARE BBB; Stable (09-Nov- 22) | 1)CARE BBB; Stable (19-Aug- 21) 2)CARE BBB-; Positive (07-Apr- 21) |
| 3 | Fund-based - LT- Cash Credit | LT | 276.00 | CARE BBB+; Stable | - | 1)CARE BBB; Stable (20-Oct- 23) | 1)CARE BBB; Stable (09-Nov- 22) | 1)CARE BBB; Stable (19-Aug- 21) |



| | | | Current Ratings | s | Rating History | | | |
|---------|--|------|------------------------------------|-------------------------|---|--|--|--|
| Sr. No. | Name of the Instrument/Bank Facilities | Туре | Amount Outstanding (₹ crore) | Rating | Date(s) and Rating(s) assigned in 2024- 2025 | Date(s) and Rating(s) assigned in 2023- 2024 | Date(s) and Rating(s) assigned in 2022- 2023 | Date(s) and Rating(s) assigned in 2021- 2022 |
| | | | | | | 2)CARE BBB; Stable (09-Oct- 23) | | 2)CARE BBB-; Positive (07-Apr- 21) |
| 4 | Fixed Deposit | LΤ | 85.00 | CARE BBB+; Stable | - | 1)CARE BBB; Stable (20-Oct- 23) 2)CARE BBB; Stable (09-Oct- 23) | 1)CARE BBB; Stable (09-Nov- 22) 2)CARE BBB; Stable (22-Jun- 22) 3)CARE BBB (FD); Stable (04-Apr- 22) | 1)CARE BBB (FD); Stable (19-Aug- 21) 2)CARE BBB (FD); Positive (29-Apr- 21) 3)CARE BBB (FD); Positive (07-Apr- 21) |

LT: Long term; ST: Short term

Annexure-3: Detailed explanation of covenants of rated instruments/facilities: Not applicable

Annexure-4: Complexity level of instruments rated

| Sr. No. | Name of the Instrument | Complexity Level |
|---------|-----------------------------|------------------|
| 1 | Fixed Deposit | Simple |
| 2 | Fund-based - LT-Cash Credit | Simple |
| 3 | Fund-based - LT-Term Loan | Simple |
| 4 | Non-fund-based - ST-BG/LC | Simple |

Annexure-5: Lender details

To view lender-wise details of bank facilities please $\underline{\text{click here}}$



Annexure-6: List of entities consolidated

| Sr No | Name of the entity | Extent of consolidation | Rationale for consolidation |
|-------|---|-------------------------|--|
| 1 | Solar Magic Private Limited | Full | Wholly owned subsidiary with operational and financial linkages |
| 2 | Cayuga Investments B.V. | Full | Wholly owned subsidiary with operational and financial linkages |
| 3 | Godavari Biorefineries B.V., Netherlands | Full | Step down overseas subsidiary being wholly owned subsidiary of Cayuga Investment B.V with operational and financial linkages |
| 4 | Godavari Biorefineries Inc, USA | Full | Step down overseas subsidiary being wholly owned subsidiary of Cayuga Investment B.V with operational and financial linkages |

Note on complexity levels of rated instruments: CARE Ratings has classified instruments rated by it based on complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for clarifications.



Contact us

Media Contact

Mradul Mishra Director

CARE Ratings Limited
Phone: +91-22-6754 3596

E-mail: mradul.mishra@careedge.in

Relationship Contact

Saikat Roy Senior Director

CARE Ratings Limited Phone: 912267543404

E-mail: saikat.roy@careedge.in

Analytical Contacts

Krunal Pankajkumar Modi

Director

CARE Ratings Limited Phone: 079-40265614

E-mail: krunal.modi@careedge.in

Arunava Paul
Associate Director
CARE Ratings Limited
Phone: 912267543667

E-mail: arunava.paul@careedge.in

Ragini Surve Lead Analyst

CARE Ratings Limited

E-mail: Ragini.Surve@careedge.in

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

For detailed Rationale Report and subscription information, please visit www.careedge.in